The COVID-19 pandemic has stunned the world with severe health and financial consequences everywhere. Researchers are actively investigating means to prevent and treat COVID-19 and an increasing number of randomized trials is being planned, conducted, and published. Convenors of the BMG are part of the steering committee of a living network meta-analysis aimed at analyzing interventions for COVID-19 .
Available evidence is continuously being collected and critically appraised for risk of bias using RoB 2. The findings are published at this website.
A key step of this living network meta-analysis is to ensure that the risk of bias assessments are performed accurately. For this purpose, the Bias Methods Group is coordinating the work of a group of experienced methodologists that are reviewing the risk of bias assessments that have been performed on the included trials. We thank the following methodologists for their valuable comments on the risk of bias assessments:
Fulvia Baldassarre; McMaster University, Canada
Rita Banzi; Center for Health Regulatory Policies, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Italy
Silvia Minozzi; Laboratory of Clinical Research Methodology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Italy
Jelena Savovic; NIHR Applied Research Collaboration West (ARC West), University Hospitals Bristol and Weston NHS Foundation Trust & Population Health Sciences, Bristol Medical School, University of Bristol, UK
Matthew Page; Research Methodology Division, School of Public Health and Preventive Medicine, Monash University, Australia